NEO NeoGenomics, Inc. - Common Stock

NAS · US · Healthcare · Diagnostics & Research · neogenomics.com

18.47USD+3.88%Mkt Cap: 2.41B $P/E: —3d ago

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clin…

Industry Peers

Diagnostics & Research

Screen all

TMO

Thermo Fisher Scientific Inc Common Stock

$242.11BUSDP/E 35.5

DHR

Danaher Corporation Common Stock

$150.48BUSDP/E 38.2

NTRA

Natera, Inc. - Common Stock

Agilent Technologies, Inc. Common Stock

$47.30BUSDP/E 33.1

IQV

IQVIA Holdings, Inc. Common Stock

$42.50BUSDP/E 32.2

WAT

Waters Corporation Common Stock

$41.75BUSDP/E 107.4

ILMN

Illumina, Inc. - Common Stock

$41.23BUSDP/E 50.8

IDXX

IDEXX Laboratories, Inc. - Common Stock

$40.89BUSDP/E 36.4

MTD

Mettler-Toledo International, Inc. Common Stock

$29.78BUSDP/E 34.0

DGX

Quest Diagnostics Incorporated Common Stock

$25.75BUSDP/E 25.0

Labcorp Holdings Inc. Common Stock

$25.02BUSDP/E 25.5

Guardant Health, Inc. - Common Stock

$23.86BUSD

RVTY

Revvity, Inc. Common Stock

$16.91BUSDP/E 72.5

MEDP

Medpace Holdings, Inc. - Common Stock

$16.73BUSDP/E 35.2

ERF

Eurofins Scientific SE

$13.92BUSDP/E 26.0

CRL

Charles River Laboratories International, Inc. Common Stock

$13.85BUSD

ICLR

ICON plc - Ordinary Shares

Qiagen N.V. Common Shares

$9.24BUSDP/E 22.7

Key Statistics

Company

Market Cap2.41B USD

Enterprise Value2.59B USD

Revenue (TTM)766.29M USD

Gross Profit314.29M USD

Net Income (TTM)-108.03M USD

Revenue/Share5.94 USD

Last Price18.47 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees2.5K

CountryUS

SectorHealthcare

IndustryDiagnostics & Research

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)52.58

PEG2.09

EV/EBITDA106.36

EV/Revenue3.38

P/S3.02

P/B2.89

EPS (TTM)-0.38

EPS (Forward)0.34

52W Range

7.07088% of range20.05

52W High20.05 USD

52W Low7.070 USD

Profitability

Gross Margin43.21%

Oper. Margin-4.84%

EBITDA Margin3.17%

Profit Margin-14.85%

ROE-12.91%

ROA-7.94%

Growth

Revenue Growth11.20%

Earnings Growth—

Cash Flow & Leverage

Operating CF5.23M USD

CapEx (TTM)27.01M USD

FCF Margin5.73%

FCF Yield1.83%

Net Debt302.83M USD

Net Debt/EBITDA12.45

Balance Sheet

Debt/Equity0.49

Current Ratio3.60

Quick Ratio3.04

Book Value/Sh6.14 USD

Cash/Share1.13 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)19.72 USD

Upside (mean)+6.8%

Target Range16.00 USD – 35.00 USD

16.00+6.8% to mean35.00

# Analysts9

Ownership

Shares Out.130.21M

Float117.02M

Insiders2.11%

Institutions115.19%

Short Interest

Short Ratio10.1d

Short % Float15.35%

Short % Out.13.01%

Shares Short16.71M

Short (prev mo.)15.88M

Technical

SMA 5017.04 (+8.4%)

SMA 20012.26 (+50.6%)

Beta1.75

S&P 52W Chg13.94%

Avg Vol (30d)1.81M

Avg Vol (10d)2.62M

Technical Indicators

RSI (14)54.2

MACD0.5448

MACD Signal0.7329

MACD Hist.-0.1881

BB Upper20.07 USD

BB Middle18.39 USD

BB Lower16.72 USD

BB Width18.20%

ATR (14)0.8540 USD

Vol Ratio (20d)1.12x